Sweet Revenge Against Superbugs
News Jul 29, 2015
A team of scientists from The University of Queensland and Queensland biotechnology company Alchemia have discovered a potential new class of antibiotics inspired by sugar molecules produced by bacteria.
New antibiotics to which bacteria are unlikely to develop resistance are urgently needed to combat the rise of superbugs – drug-resistant bacteria.
Professor Cooper, Director of the IMB Centre for Superbug Solutions, said bacteria were less likely to become resistant to an antibiotic based on a modified version of their own sugar.
“Bacteria have cell walls similar to the walls of a brick house, except instead of mortar the walls are held together by sugar polymers,” Professor Cooper said.
“But if you add one of our modified sugar molecules, they stop the linking process, destroying the cell wall and killing the bacteria.”
“The cell wall has been a target for antibiotics such as penicillin and vancomycin before, but the difference here is that we are stopping a centrally important part of the cell wall linking process.”
Dr Zuegg said the team examined hundreds of versions of Alchemia’s modified sugar molecules to find those that will kill bacteria and are non-toxic to human cells.
“Most molecules screened to become drugs have a flat, planar shape, whereas these molecules are three dimensional,” Dr Zuegg said.
“This means we can build on the sugar core in a variety of ways to make thousands of different combinations in three dimensional space.
The team included researchers from the University of Warwick in the UK, Academia Sinica in Taiwan and Ghent University in Belgium.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.